Accelerated Scale-Up Process for Biologics Manufacturing

This case study outlines a strategy developed to enhance the scale-up process of monoclonal antibody production from a 3 L bioreactor to a 2,000 L bioreactor without requiring intermediate volumes. The document details the importance of scalability in the biotech industry, particularly during clinical development, where timely production is crucial. It describes the challenges faced in traditional scaling initiatives, which typically involve multiple intermediate steps and can extend the timeline significantly. The approach taken involved a direct tech transfer strategy that maintained process stability and efficiency, leveraging knowledge from process development and utilizing specific models to ensure consistent conditions across different bioreactor sizes. The outcome demonstrated that this method could eliminate the need for intermediate scale steps, thereby accelerating the time to market and providing a competitive advantage. The case study emphasizes the integration of expertise in contract testing, development, and manufacturing to offer comprehensive solutions for clients in the biotech sector.